Rory B. Riggs
Chief Executive Officer at Cibus Inc.
Sits on 2 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Royalty Pharma plc, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cibus Inc. June 2, 202699.4%
-
Cibus Inc. May 30, 202499.7%
-
Royalty Pharma plc June 22, 202399.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 29, 2026 | Cibus Inc. | Grant or award | +333,333 | $1.50 | $500,000 |
| Jun 9, 2025 | Cibus Inc. | In-the-money exercise | +4,000,000 | — | — |
| Jun 9, 2025 | Cibus Inc. | In-the-money exercise | +50,000 | $0.01 | $500 |
| Jun 5, 2025 | Cibus Inc. | Grant or award | +5,714,286 | $1.75 | $10,000,001 |
| Dec 31, 2024 | Cibus Inc. | Derivative conversion | −1,388,084 | — | — |
| Dec 31, 2024 | Cibus Inc. | Derivative conversion | +1,388,084 | — | — |
| Sep 18, 2024 | Cibus Inc. | Grant or award | +250,000 | $4.00 | $1,000,000 |
| Jun 11, 2024 | Cibus Inc. | Grant or award | +98,040 | $10.20 | $1,000,008 |
| Feb 20, 2024 | Royalty Pharma plc | Derivative conversion | +300,000 | — | — |
| Jan 4, 2024 | Royalty Pharma plc | Open-market sale | −35,702 | $27.55 | $983,590 |
| Jan 3, 2024 | Royalty Pharma plc | Open-market sale | −199,098 | $27.79 | $5,532,933 |
| Jan 2, 2024 | Royalty Pharma plc | Open-market sale | −235,200 | $28.52 | $6,707,904 |
| Dec 29, 2023 | Cibus Inc. | Other | +1,505,967 | — | — |
| Dec 29, 2023 | Cibus Inc. | Derivative conversion | −1,500,000 | — | — |
| Dec 29, 2023 | Cibus Inc. | Derivative conversion | +1,500,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.